Další formáty:
BibTeX
LaTeX
RIS
@article{1217807,
author = {Kubatka, Peter and Kružliak, Peter and Rotrekl, Vladimír and Jelínková, Šárka and Mladosievicova, Beata},
article_location = {New York},
article_number = {3},
doi = {http://dx.doi.org/10.1016/j.critrevonc.2014.08.002},
keywords = {Anti-tumor properties; Cancer risk reduction; Cancer therapy; Carcinogenesis; Chemoprevention; Statins},
language = {eng},
issn = {1040-8428},
journal = {Critical Reviews in Oncology/Hematology},
title = {Statins in oncological research: From experimental studies to clinical practice},
volume = {92},
year = {2014}
}
TY - JOUR
ID - 1217807
AU - Kubatka, Peter - Kružliak, Peter - Rotrekl, Vladimír - Jelínková, Šárka - Mladosievicova, Beata
PY - 2014
TI - Statins in oncological research: From experimental studies to clinical practice
JF - Critical Reviews in Oncology/Hematology
VL - 92
IS - 3
SP - 296-311
EP - 296-311
PB - Elsevier Science Inc.
SN - 10408428
KW - Anti-tumor properties
KW - Cancer risk reduction
KW - Cancer therapy
KW - Carcinogenesis
KW - Chemoprevention
KW - Statins
N2 - Statins, 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors are commonly used drugs in the treatment of dyslipidemias, primarily raised cholesterol. Recently, many epidemiological and preclinical studies pointed to anti-tumor properties of statins, including anti-proliferative activities, apoptosis, decreased angiogenesis and metastasis. These processes play an important role in carcinogenesis and, therefore, the role of statins in cancer disease is being seriously discussed among oncologists. Anti-neoplastic properties of statins combined with an acceptable toxicity profile in the majority of individuals support their further development as anti-tumor drugs.The mechanism of action, current preclinical studies and clinical efficacy of statins are reviewed in this paper. Moreover, promising results have been reported regarding the statins' efficacy in some cancer types, especially in esophageal and colorectal cancers, and hepatocellular carcinoma. Statins' hepatotoxicity has traditionally represented an obstacle to the prescription of this class of drugs and this issue is also discussed in this review.
ER -
KUBATKA, Peter, Peter KRUŽLIAK, Vladimír ROTREKL, Šárka JELÍNKOVÁ a Beata MLADOSIEVICOVA. Statins in oncological research: From experimental studies to clinical practice. \textit{Critical Reviews in Oncology/Hematology}. New York: Elsevier Science Inc., 2014, roč.~92, č.~3, s.~296-311. ISSN~1040-8428. Dostupné z: https://dx.doi.org/10.1016/j.critrevonc.2014.08.002.
|
